CORE OF MOULD WHICH CAN BE DESTROYED FOR THE METAL CAST IRON, BE PROCEEDED DEFABRICATION AND USE

Compensation plate for expansion joints in railway bridges

The plate (1) consists of a supporting construction of reinforced concrete, prestressed concrete, steel, or sandwich construction, and covers the joints (4) at the ends of a bridge below a track. The plate is held elastically sliding on the two ends of the bridge track, or on one end and an abutment, so that the overall movement of the joint consisting of sliding (2) and turning movements (3), is divided into smaller movements at the ends of the compensation plate.

PRESSURE PLATE ASSEMBLY FOR A FRICTION CLUTCH

COMPOSING FOR BOXES PROTECT BY SHIELDING AGAINST THE HIGH FREQUENCIES

Gleitringdichtungsanordnung mit Rutschkupplung

Die Erfindung betrifft eine Gleitringdichtungsanordnung, umfassend einen rotierenden Gleitring (2) und einen stationären Gleitring (3), welche zwischen sich einen Dichtspalt (4) definieren, und eine Rutschkupplungseinrichtung (7), welche in einem Drehmomentübertragungspfad zwischen rotierenden Bauteilen und/oder in einem drehmomentabstützenden Pfad zwischen stationären Bauteilen angeordnet ist, wobei die Rutschkupplungseinrichtung (7) bei Auftreten eines über einem vorbestimmten Schwellenwert liegenden Drehmoments eingerichtet ist, eine in Umfangsrichtung auftretenden Rutschvorgang zuzulassen.

Graphische Diagnosedarstellung von Druckköpfen

Ein Verfahren zum Diagnostizieren eines Druckkopfstatus, umfassend:Diagnostizieren (510), welche einer Anzahl von Düsen (306-1 ... 306-N, 306-M) Tinte in einem ersten Druckkopf (202, 300) abfeuern, unter Verwendung eines Tropfendetektors (308-1 ... 308-N, 308-M); undDrucken einer graphischen Diagnosedarstellung (416, 520) unter Verwendung eines zweiten Druckkopfes (202, 300), die die Düsen (306-1 ... 306-N, 306-M), die Tinte aus dem ersten Druckkopf (202, 300) abfeuern, abbildet,wobei eine Düse (414) an dem zweiten Druckkopf (202, 300) deaktiviert wird, wenn eine entsprechende Düse (306-1 ... 306-N, 306-M) an dem ersten Druckkopf (202, 300) keine Tinte abfeuert.

Kraftstoffeinfülldeckel-Betätigungselement und Kraftfahrzeuge

Diese Erfindung bietet einen Art Kraftstoffeinfülldeckel-Betätigungselement und Kraftfahrzeug, umfassend: Schraubenwelle, Rotor, Gehäuse, erste Rückstellfeder, Sperrblock und Sperrblock-Antriebsvorrichtung; Unter der Wirkung der Sperrblock-Antriebsvorrichtung, kann der Sperrblock zwischen dem Sperrwinkel und dem Entsperrwinkel gedreht werden; die Sperrblock-Antriebsvorrichtung wendet ein elektromagnetisches Antriebsverfahren zum Antreiben des Sperrblocks an. Dadurch ist ein Motorantrieb nicht erforderlich und das Sperren/Entsperren des Kraftstoffeinfülldeckels durch die Wechselwirkung des ersten und zweiten Magneten wird ermöglicht, wodurch die Betriebskosten wesentlich reduziert werden und die Lebensdauer verlängert wird.

LUBRIFYING AGENT FOR SEPARATING POLYURETHANE FOAMED PLASTIC ITEMS FROM THE MOULD

Pichia ciferrii Zellen und deren Verwendung

Gegenstand der Erfindung sind gentechnisch modifizierte Pichia ciferri Zellen, deren Verwendung sowie ein Verfahren zur Herstellung von Sphingoidbasen und Sphingolipiden.

Neue Enzyme

Gegenstand der Erfindung sind neue Enzyme, die acetylierte Sphingoidbasen bereitstellen.

Gleitringdichtungsanordnung mit Rutschkupplung

Die Erfindung betrifft eine Gleitringdichtungsanordnung, umfassend einen rotierenden Gleitring (2) und einen stationären Gleitring (3), welche zwischen sich einen Dichtspalt (4) definieren, und eine Rutschkupplungseinrichtung (7), welche in einem Drehmomentübertragungspfad zwischen rotierenden Bauteilen und/oder in einem drehmomentabstützenden Pfad zwischen stationären Bauteilen angeordnet ist, wobei die Rutschkupplungseinrichtung (7) bei Auftreten eines über einem vorbestimmten Schwellenwert liegenden Drehmoments eingerichtet ist, eine in Umfangsrichtung auftretenden Rutschvorgang zuzulassen.

Method for preventing the contamination by platinum of an SCR catalyst

The invention relates to a method for preventing the contamination by platinum of an SCR catalyst in an exhaust-gas treatment system, said system comprising an oxidation catalyst containing platinum on the inflow side of the SCR catalyst. The outflow side of the oxidation catalyst comprises a material zone which removes traces of platinum contained in the exhaust-gas stream.

PALMITATED MONOCLONAL ANTIBODY

The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). 1104.-. (canceled)105. An isolated antibody , or an active fragment thereof , which recognizes a conformational epitope of polymeric soluble amyloid peptides comprising a plurality of monomeric Aβ1-42 peptides.106. The antibody or active fragment thereof according to claim 105 , which binds to Aβ monomeric peptide 1-40 claim 105 , or soluble polymeric or oligomeric amyloid peptide claim 105 , comprising a plurality of Aβ1-42 monomeric peptides claim 105 , wherein the antibody or active fragment thereof has essentially no binding to Aβ monomeric peptide 17-40 claim 105 , substantially weaker binding to Aβ monomeric peptide 1-28 claim 105 , or an intermediate level of binding to monomeric peptide 1-42.107. The antibody or active fragment thereof according to claim 105 , which upon co-incubation with an Aβ peptide comprising at least 30 claim 105 , at least 35 claim 105 , at least 38 claim 105 , at least 40 claim 105 , or 42 amino acid residues in a monomeric or an ...

Pharmaceutical Composition

The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical composition comprising an antigenic peptide, particularly an antigenic phospho-peptide mimicking a major pathological phospho-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease. 1193-. (canceled)194. An antigenic peptide obtainable from a tau protein which peptide is modified through linkage to a lipophilic or hydrophobic moiety that facilitates insertion into the lipid bilayer of a liposome , wherein said antigenic peptide is reconstituted in a liposome such that the peptide is presented in a highly repetitive array on the surface of the liposome.195. The antigenic peptide of claim 194 , wherein said peptide consists of between 5 and 25 amino acid residues claim 194 , or is a functional fragment thereof.196. The antigenic peptide of claim 194 , wherein said peptide is capable of eliciting a conformation specific and/or a T-cell independent immune response.197. The peptide or fragment of claim 194 , which has an amino acid sequence ofa. SEQ ID NO: 2 or an amino acid sequence of SEQ ID NO: 2 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same or essentially the same antigenic potential as the unmodified sequence; orb. SEQ ID NO: 3 or an amino acid sequence of SEQ ID NO: 3 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same or essentially the same antigenic potential as the unmodified sequence; orc. SEQ ID NO: 4 or an amino acid sequence of SEQ ID NO: 4 modified through conservative substitution, deletion or insertion of at least one but not more than 5 ...

METHODS OF TREATING AMYLOIDOSIS COMPRISING THE USE OF ANTI-AMYLOID BETA ANTIBODIES

The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. 2. The method of wherein the antibody or antigen-binding fragment comprises:a. a LCVR comprising a LCVR CDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCVR CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCVR CDR3 comprising the amino acid sequence of SEQ ID NO: 25; andb. a HCVR comprising a HCVR CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCVR CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCVR CDR3 comprising the amino acid sequence of SEQ ID NO: 28.3. The method of claim 1 , wherein the amyloidosis is Alzheimer's Disease.4. The method of claim 2 , wherein the amyloidosis is Alzheimer's Disease.5. A method for retaining or increasing cognitive memory capacity in a mammal comprising administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof claim 2 , wherein the monoclonal antibody or antigen-binding fragment thereof is capable of specifically binding beta-amyloid claim 2 , and wherein the antibody or antigen-binding fragment comprises:a. a LCVR comprising a LCVR CDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCVR CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a LCVR CDR3 comprising the amino acid sequence of SEQ ID NO: 25; orb. a HCVR comprising a HCVR CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a HCVR CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a HCVR CDR3 comprising the amino acid sequence of SEQ ID NO: 28.6. The method of wherein the antibody or antigen-binding fragment comprises:a. a LCVR comprising a LCVR CDR1 comprising the amino acid sequence of SEQ ID NO: 23, a LCVR ...

NUCLEIC ACID MOLECULES ENCODING ANTI-AMYLOID-BETA ANTIBODIES

The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the light chain variable region of an antibody , or a fragment thereof , which antibody specifically binds to monomeric , oligomeric or polymeric forms of amyloid-β , wherein:(i) complementarity determining region 1 (CDR1) of the light chain variable region of the antibody has the amino acid sequence of SEQ ID NO:23;(ii) CDR2 of the light chain variable region of the antibody has the amino acid sequence of SEQ ID NO:24; and(iii) CDR3 of the light chain variable region of the antibody has the amino acid sequence of SEQ ID NO:25.2. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the heavy chain variable region of an antibody , or a fragment thereof , which antibody specifically binds to monomeric , oligomeric or polymeric forms of amyloid-β , wherein:(i) CDR1 of the heavy chain variable region of the antibody has the amino acid sequence of SEQ ID NO:26;(ii) CDR2 ...

System and method of generating a route across an electronic map

A computerised method of generating a route 1000 from an origin position F 1 to a destination position 706 across an electronic map 700 comprising a plurality of vectors representing segments of a navigable route in the area covered by the electronic map 700, the method comprising: (1) obtaining delay data indicating delays on vectors within the area covered by the electronic map 700; (2) calculating a first portion 1002 of a route from origin position toward the destination position 706 using a first routing method up to a predetermined threshold 1006 from the origin position F 1, such that the first routing method uses the delay data so that the first portion 1002 of the route takes into account delays; and (3) calculating a second portion 1004 of the route beyond the predetermined threshold 1006 to the destination position 706 using a second routing method to further calculate the route to the destination position 1006.

HUMANIZED ANTIBODY

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. A humanized antibody or a fragment thereof capable of specifically binding beta-amyloid , wherein the humanized antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising human- or primate-derived heavy chain framework regions and complementarity determining regions (CDRs) 1 , 2 and 3 comprising the amino acid sequence of SEQ ID NO: 1 representing CDR1 , SEQ ID NO: 2 representing CDR2 and SEQ ID NO: 3 representing CDR3 of the HCVR , particularly in the order indicated.16. A humanized antibody or a fragment thereof capable of specifically binding beta-amyloid , wherein the humanized antibody or fragment thereof comprises a light chain variable region (LCVR) comprising human- or primate-derived light chain framework regions and CDRs 1 , 2 , and 3 comprising the amino acid sequence of SEQ ID NO: 4 representing CDR1 , SEQ ID NO: 5 or SEQ ID NO: 5 with an amino acid substitution representing CDR2 and SEQ ID NO: 6 representing CDR3 of the LCVR , particularly in the order indicated.17. (canceled)18. (canceled)19. (canceled)20. The humanized antibody or fragment thereof according to claim 16 , wherein the humanized antibody or fragment thereof further comprises an HCVR comprising human- or primate-derived framework regions and CDRs 1 claim 16 , 2 claim 16 , and 3 comprising the amino acid sequence of SEQ ID NO: 1 representing CDR1 claim 16 , SEQ ID NO: 2 representing CDR2 and SEQ ID NO: 3 representing CDR3 of the HCVR.21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. ...

Liposome-Based Construct Comprising a Peptide Modified Through Hydrophobic Moieties

The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease. 1. A method of preparing a liposome-based construct comprising a peptide modified through hydrophobic moieties reconstituted in a liposome , comprising the steps ofi preparing liposomes in a solution;ii preparing a modified peptide by adding to the N- and/or C-terminus of the peptide molecule at least one hydrophobic moietyiii solubilizing the modified peptide in the presence of a surfactant;iv diluting the solubilized peptide below the critical micellar concentration of the surfactant;v loading the preformed liposomes with the diluted solubilized peptide by adding said peptide to the preformed liposomal preparation and solubilizing the added peptide into the external layer of the liposomes.2. The method of claim 1 , wherein said peptide is an antigenic peptide.3. The method of claim 2 , wherein the preformed liposomes are further loaded with an adjuvant.4. The method of claim 3 , wherein the adjuvant loading is carried out (a) prior to; (b) together with; or (c) after the loading of the liposomes with the diluted solubilized antigenic peptide.5. The method of or claim 3 , wherein the adjuvant is lipid A claim 3 , particularly detoxified lipid A claim 3 , such as monophosphoryl or diphosphoryl lipid A claim 3 , alum claim 3 , Pam2CSK4 claim 3 , Pam3CSK4 claim 3 , Pam3CAG claim 3 , saponins claim 3 , CpG claim 3 , phosphorothioated PS-CpG-ODNs claim 3 , lipidated CpG claim 3 , oligodeoxynucleotides (CpG-ODN) such as CpG-A claim 3 , CpG-B or CpG-C claim 3 , cationic lipids.6. The ...

Monoclonal Antibody

The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). 1. A monoclonal antibody including any functionally equivalent antibody or functional parts thereof , which antibody recognizes and binds to a conformational epitope and binds to polymeric soluble amyloid and to amyloid fibrils or fibers , respectively , particularly to polymeric soluble Aβ peptides comprising a plurality of Aβmonomeric peptides and Aβ fibrils or fibers incorporating a plurality of said polymeric peptides , respectively.2. A monoclonal antibody according to including any functionally equivalent antibody or functional parts thereof claim 1 , which antibody binds to Aβ monomeric peptide 1-42 but shows a substantially weaker binding to Aβ monomeric peptide 1-28.3. A monoclonal antibody according to including any functionally equivalent antibody or functional parts thereof claims 1 , which antibody binds to Aβ monomeric peptide 1-42 but shows a substantially weaker binding to Aβ monomeric peptide 1-28 and essentially no binding to Aβ monomeric peptide ...

Artificial snow-making facility

The present invention relates to an artificial snow-making facility (1) comprising—a snow-making device (2),—a fluidic water pipe (3) for supplying water to said snow-making device (2),—potentially, a fluidic air pipe (4) for supplying air to said snow-making device (2),—control means (5) for managing the operation of said snow-making device (2),—a power supply for supplying electricity to said control means (5).According to the invention, said power supply comprises a power generator (6) arranged on one of said fluidic pipes (4),said power generator (6) comprising a turbine (61) adapted to be driven by the fluid of said fluidic pipe (4).

2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. 2. The method of claim 1 , wherein Rand Rare independently selected from hydrogen and methyl.3. The method of claim 1 , wherein q is 2.9. The method of claim 8 , wherein the ocular disease comprises glaucoma.10. The method of claim 9 , wherein the glaucoma comprises: chronic (idiopathic) open-angle glaucoma claim 9 , pupillary block glaucoma claim 9 , developmental glaucoma claim 9 , glaucoma associated with other ocular disorders claim 9 , glaucoma associated with elevated episcleral venous pressure claim 9 , glaucoma associated with inflammation and trauma claim 9 , glaucoma following intraocular surgery claim 9 , high-pressure glaucoma claim 9 , normal-pressure glaucoma claim 9 , acute angle-closure glaucoma claim 9 , subacute angle-closure glaucoma claim 9 , chronic angle-closure glaucoma claim 9 , combined mechanism glaucoma claim 9 , congenital (infantile) glaucoma claim 9 , juvenile glaucoma aniridia claim 9 , glaucoma associated with disorders of the corneal endothelium claim 9 , glaucoma associated with disorders of the iris and ciliary body claim 9 , glaucoma associated with disorders of the lens claim 9 , glaucoma associated with disorders of the retina claim 9 , choroid claim 9 , and vitreous claim 9 , glaucoma associated with retinal detachment and vitreoretinal abnormalities claim 9 , neovascular glaucoma claim 9 , pigmentary glaucoma claim 9 , exfoliation syndrome claim 9 , lens-induced open-angle glaucoma claim 9 , glaucoma associated with lens intumescence and dislocation claim 9 , glaucoma associated with keratitis claim 9 , ...

ANTI-TAU ANTIBODIES AND METHODS OF USE

The present invention relates to anti-Tau antibodies, such as antibodies that bind to a phosphorylated epitope on human Tau protein with high specificity and/or affinity, and methods of using the same. 1. An isolated antibody that binds to a phosphorylated epitope of Tau protein , wherein the antibody comprises at least one sequence selected from the group consisting of HVR-L1 , HVR-L2 and HVR-L3 , wherein:{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '1', '2', '3', '4', '5', '6', '7', '8, '(a) HVR-L1 comprises the amino acid sequence XSSQXLXXXXGXTYXH (SEQ ID NO:89), wherein X=R or T; X=S, R or V; X=V, I or R; X=H or R; X=S, R, G or K; X=H, N, R, K or G; X=K or R; and X=L or V;'}{'sub': 9', '10', '11', '9', '10', '11, '(b) HVR-L2 comprises the amino acid sequence KVXXRFX(SEQ ID NO:90), wherein X=S, K or R; X=N, K or H; and X=S, F, G, K, R, Y or L; and'}{'sub': 12', '13', '14', '12', '13', '14, '(c) HVR-L3 comprises the amino acid sequence SQTXXFPXT (SEQ ID NO:91), wherein X=A or R; X=H, R, Q or Y; X=Y or R;'}and wherein the antibody does not comprise an HVR-L1, HVR-L2 and HVR-L3 wherein the HVR-L1 amino acid sequence is RSSQSLVHSHGKTYLH (SEQ ID NO:15) or RSSQRLVHSHGKTYLH (SEQ ID NO:92); the HVR-L2 amino acid sequence is KVSNRFS (SEQ ID NO:16); and the HVR-L3 amino acid sequence is SQTAHFPYT (SEQ ID NO:30).2. The antibody of claim 1 , wherein the phosphorylated epitope includes a phosphorylated amino acid residue selected from the group consisting of serine at position 409 of human tau (SEQ ID NO:59); serine at position 404 of human tau (SEQ ID NO:59); and serine at position 404 and 409 of human tau (SEQ ID NO:59).3. The antibody of any one of or claim 1 , wherein the antibody comprises at least one sequence selected from the group consisting of HVR-H1 claim 1 , HVR-H2 and HVR-H3 claim 1 , wherein HVR-H1 comprises the amino acid sequence GYTFTDYYMN (SEQ ID NO:33); HVR-H2 comprises the amino acid sequence DINPNRGGTTYNQKFKG (SEQ ID NO:34); and HVR-H3 comprises the ...

Automated video content processing

Video content is processed for delivery using an automated process that allows for convenient packaging of encrypted or digital rights management (DRM) protected content in a manner such that the packaged content can be efficiently stored in a content delivery network (CDN) or other content source for subsequent re-use by other media clients without re-packaging, and without excessive storage of unused content data.

HUMANIZED ANTIBODY IGG1

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. 1. A chimeric antibody or a fragment thereof , or a humanized antibody or a fragment thereof , which specifically binds to at least one epitope on the β-amyloid protein wherein the epitope comprises at least two consecutive amino acid residues predominantly involved in binding to the antibody , wherein the at least two consecutive amino acid residues are -Lys-Leu- embedded within the following core sequence (SEQ ID NO: 10):{'sub': 1', '2', '3, 'Xaa-Xaa-Lys-Leu-Xaawherein'}{'sub': '1', 'Xaais an amino acid selected from the group consisting of His, Asn, Gln, Lys, and Arg,'}{'sub': '2', 'Xaais an amino acid selected from the group consisting of Asn and Gln; and'}{'sub': '3', 'Xaais an amino acid selected from the group consisting of Ala, Val, Leu, norleucine, Met, Phe, and Ile.'}2. A chimeric antibody or a fragment thereof , or a humanized antibody or a fragment thereof , which specifically binds to at least one epitope on the β-amyloid protein wherein the said epitope comprises at least two consecutive amino acid residues predominantly involved in the binding to the antibody , wherein the at least two consecutive amino acid residues are -Phe-Phe- embedded within the following core sequence (SEQ ID NO: 9):{'sub': 3', '4', '5', '6, 'Xaa-Phe-Phe-Xaa-Xaa-Xaa, wherein'}{'sub': '3', 'Xaais an amino acid residue selected from the group consisting of Ala, Val, Leu, norleucine, Met, Phe, and Ile;'}{'sub': '4', 'Xaais an amino acid residue selected from the group consisting of Ala, Val, Leu, Ser and Ile;'}{'sub': '5', 'Xaais an amino acid residue selected from the group consisting of Glu and Asp, and'}{'sub': '6', 'Xaais an amino acid residue selected from the group consisting of Glu and Asp.'}360.-. (canceled ...

Fastener having an inner undercut region

A fastening means, in particular for a bellows, comprises a male end segment and a female end segment complementary to the male end segment. The fastening means can be used to fasten bellows to joint housings and/or shafts. The fastening means has an inner undercut region in order to provide an improved closing behavior of the fastening means.

Catheter for the directional conveyance of a fluid, particularly a body fluid

A catheter for the directional conveyance of a fluid, in particular a body fluid, is provided. The catheter includes a sleeve having an internal space and a frame. The sleeve has at least three openings and is configured at least in a region between the first opening and the second opening as a conduit for the fluid. A check valve is arranged at the second opening. The check valve includes a valve foil which is at least partially attached to the sleeve such that the second opening can be completely covered by the valve foil.

HUMANIZED ANTIBODY

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. 1152.-. (canceled)153. An artificial hybrid antibody comprising two different heavy/light chain pairs and two different binding sites , or fragment thereof , wherein a first heavy/light chain pair is capable of specifically binding beta-amyloid and comprises:(A) (i) a humanized light chain comprising the amino acid sequence of SEQ ID NO: 13; and (ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16; or(B) (i) a humanized light chain comprising the amino acid sequence of SEQ ID NO: 13; and (ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16 lacking the C-terminal Lys at position 439; or '(ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16 lacking the C-terminal Lys at position 439.', '(C) (i) a humanized light chain comprising a light chain variable region (LCVR), wherein the LCVR comprises human-derived light chain framework regions, the amino acid sequence of SEQ ID NO: 4 representing complementarity determining region (CDR)1 of the LCVR, the amino acid sequence of SEQ ID NO: 5, the amino acid RVSNRFS, or the amino acid sequence KVSSRFS, representing CDR2 of the LCVR, and the amino acid sequence of SEQ ID NO: 6 representing CDR3 of the LCVR; and'}154. A nucleic acid molecule comprising a nucleotide sequence encoding the artificial hybrid antibody or fragment thereof according to .155. An expression vector comprising the nucleic acid molecule of .156. A cell comprising the expression vector of .157. A method for preventing claim 153 , treating or alleviating the effects of amyloidosis claim 153 , a group of diseases and disorders associated with amyloid plaque formation in a subject claim 153 , comprising ...

Ecg based future atrial fibrillation predictor systems and methods

A method and system for predicting the likelihood that a patient will suffer from atrial fibrillation is provided. The method includes receiving electrocardiogram data associated with the patient, providing at least a portion of the electrocardiogram data to a trained model, receiving a risk score indicative of the likelihood the patient will suffer from atrial fibrillation within a predetermined period of time from when the electrocardiogram data was generated, and outputting the risk score to at least one of a memory or a display for viewing by a medical practitioner or healthcare administrator. The system includes at least one processor executing instructions to carry out the steps of the method.

Compressor for producing a pressure medium

In the case of a compressor for generating a pressure medium, in particular for dispensing a tire sealing agent from a vessel, wherein a piston ( 6, 6.1 ) is arranged in a pressure chamber ( 7 ) so as to be movable along an axis ( 3 ) and said piston ( 6, 6.1 ) is assigned a motor ( 1 ) which effects the movement of the piston ( 6, 6.1 ), it is the intention for a drive shaft ( 2 ) of the motor ( 1 ) to be arranged in the axis ( 3 ) of the piston ( 6, 6.1 ) or parallel thereto.

Caching recorded content segments on playback

Methods and apparatus are disclosed for efficient storage and retrieval of content items, such as recorded content items of a cloud DVR system or other system storing content items.

PHOSPHOSPECIFIC ANTIBODIES RECOGNISING TAU

The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD). 166.-. (canceled)67. A method for diagnosing a tau-protein-associated disease , disorder or condition or a predisposition to tau-protein-associated disease , disorder or condition in a patient comprising detecting the immunospecific binding of an antibody or an antigen binding fragment thereof to a tau protein in a sample from the patient , wherein the antibody or antigen binding fragment thereof antibody comprises a light chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 106 , a CDR2 comprising the amino acid sequence of SEQ ID NO: 107 , and a CDR3 comprising the amino acid sequence of SEQ ID NO: 108; and a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 89 , a CDR2 comprising the amino acid sequence of SEQ ID NO: 115 , and a CDR3 comprising the amino acid sequence of SEQ ID NO: 91 ,wherein an increase in the amount of tau protein compared to a normal control value indicates that said patient is suffering from or is at risk of developing a tau protein-associated disease, disorder or condition.68. A method for monitoring minimal residual disease in a patient following treatment with an anti-tau antibody , comprising detecting the immunospecific binding of an antibody or an antigen binding fragment thereof to a tau protein in a sample from the patient , wherein the antibody or antigen binding fragment thereof antibody comprises a light chain variable region comprising a CDR1 ...

Transformer for a dc/dc voltage converter

A transformer for a DC-DC converter, such as a resonant converter, is provided. The converter includes a transformer unit that includes at least one winding with a first winding connection and a second winding connection, and a capacitor assembly consisting of at least one capacitor with a first capacitor assembly connection and a second capacitor assembly connection. The capacitor assembly is arranged so as to lie against the transformer unit in order to form an assembly. The capacitor assembly connections are connected to the winding connections via one or more first connection parts in a specified manner with respect to the electric connections. The capacitor assembly connections and/or the winding connections are electrically connected to multiple second connection parts in a specified manner with respect to the electric connections for connecting to a first power module and a second power module.

HUMANIZED ANTIBODY IGG1

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. 1155.-. (canceled)156. A humanized antibody or a fragment thereof capable of specifically binding beta amyloid , wherein the humanized antibody or fragment thereof comprises:(i) a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 representing complementarity determining region (CDR)1 of the HCVR, the amino acid sequence of SEQ ID NO: 2 representing CDR2 of the HCVR, and the amino acid sequence of SEQ ID NO: 3 representing CDR3 of the HCVR;(ii) a light chain variable region (LCVR) comprising amino acid sequence of SEQ ID NO: 4 representing CDR1 of the LCVR, the amino acid sequence of SEQ ID NO: 5, the amino acid RVSNRFS, or the amino acid sequence KVSSRFS, representing CDR2 of the LCVR, and the amino acid sequence of SEQ ID NO: 6 representing CDR3 of the LCVR; and(iii) an IgG1 Fc region comprising an amino acid modification in one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439, which amino acid modification results in a reduced effector function.157. A humanized antibody or a fragment thereof capable of specifically binding beta amyloid , wherein the humanized antibody or fragment thereof comprises:(i) a heavy chain variable region (HCVR) that is at least 95% identical to the sequence of SEQ ID NO: 15, wherein the HCVR comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 3;(ii) a light chain variable region (LCVR) that is at least 95% ...

HUMANIZED TAU ANTIBODY

The present invention provides, methods end composites for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the Invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to methods and compositions involving antibodies for the therapeutic and diagnostic use In the treatment of tauopathies including Alzheimer's Disease (AD). 17.-. (canceled)8. The humanized antibody of claim 10 , or a functional fragment thereof claim 10 , whereina. the HCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO: 1, a CDR2 with the amino acid sequence shown in SEQ ID NO: 2, and a CDR3 with the amino acid sequence shown in SEQ ID NO: 3, and/or wherein the LCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO: 4, a CDR2 with the amino acid sequence shown in SEQ ID NO: 5, and a CDR3 with the amino acid sequence shown in SEQ ID NO: 6; orb. the HCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO: 1, a CDR2 with the amino acid sequence shown in SEQ ID NO: 2, and a CDR3 with the amino acid sequence shown in SEQ ID NO: 3, and/or wherein the LCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO: 10, a CDR2 with the amino acid sequence shown in SEQ ID NO: 5, and a CDR3 with the amino acid sequence shown in SEQ ID NO: 6.9. (canceled)10. A humanized antibody claim 10 , or a functional fragment thereof claim 10 , which antibody recognizes and specifically binds to a phospho-epitope on a human Tau protein as shown in SEQ ID NO: 19 or on a fragment thereof claim 10 , but does not bind to the corresponding unphosphorylated epitope and/or to non-related epitopes claim 10 , wherein said epitope comprises Tau aa 404-411 with the requirement of a phosphorylated Ser at position 409 (pS409) claim 10 , wherein said antibody or antibody fragment comprises aa. first ...

Catheter

The invention relates to a catheter for the directional conductance of a body fluid, particularly blood. The catheter includes a line segment which has a film tube defining an inner volume. A first port connects the inner volume to an external volume and a second port, arranged distally from the first port, connects the inner volume with the external volume. During operation of the catheter, the body fluid is conducted in the inner volume directionally between the first and second ports. The line segment includes a reinforcement running in the interior of the film tube. The film tube has a foldable section, a connecting region whereat the film tube is connected to the reinforcement, and a stabilized section having a structured profile.

PHOSPHOSPECIFIC ANTIBODIES RECOGNISING TAU

The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD). 1. An antibody , or a functional fragment thereof , which recognizes and specifically binds to a phospho-epitope on the mammalian Tau protein or on a fragment thereof , wherein said antibody or antibody fragment has a high binding affinity to soluble , oligomeric and insoluble phosphorylated Tau protein and is capable of detecting and/or modulating levels of soluble , oligomeric and insoluble phosphorylated Tau protein in vivo.2. An antibody or a functional fragment thereof , wherein said antibody or antibody fragment binds to a phospho-epitope having , or within , the amino acid sequence VYKSPWSGDTSPRHL (SEQ ID NO: 62) (Tau aa 393-408 of SEQ ID NO: 67) comprising a phosphorylated Ser at position 396 (pS396) and at position 404 (pS404).3. The antibody of or a functional fragment thereof claim 2 , wherein said antibody or antibody fragment is a modulating antibody which modulates soluble and/or insoluble Tau levels in the brain of a mammal.4. The antibody of or a functional fragment thereof claim 3 , wherein said antibody or antibody fragment modulates soluble and/or insoluble Tau levels in brain cortex and/or hippocampus.5. The antibody of any one of the preceding claims or a functional fragment thereof claim 3 , wherein said antibody or antibody fragment reduces the levels of total soluble and/or insoluble tau protein.6. The antibody of any one of the preceding claims or a functional fragment thereof claim 3 , wherein said antibody or antibody fragment reduces ...

Exosomal microrna in serum as an indicator for the activation of brown and beige fat tissue (bat)

The present invention relates to methods for detecting activation of a brown/beige fat cell or brown/beige adipose tissue (BAT) in a biological sample taken from a mammal to be diagnosed, comprising measuring the amount of miR-92 in said sample. The invention further-more relates to diagnostic and clinical applications of the methods of the invention.

IL-18 BINDING PROTEIN (IL-18BP) IN INFLAMMATORY DISEASES

The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications. 187-. (canceled)88. A method of determining the amount of free IL-18 in a sample or in situ comprising detecting the specific binding of the IL-18 binding molecule to free IL-18 protein in the sample or in situ which includes the steps of:a) bringing a sample or a specific body part or body area suspected to contain free IL-18 into contact with the IL-18 binding molecule, which specifically binds to free IL-18, but not to IL-18 bound in a complex and functions as the capturing molecule for free IL-18;b) allowing the IL-18 binding molecule to bind to free IL-18;c) detecting the binding of IL-18 to the IL-18 binding molecule, and determining the amount of free IL-18 in the sample.89. The method of claim 88 , wherein the inhibitor is an IL-18 binding molecule claim 88 , particularly an IL-18 binding molecule specifically binding free IL-18 claim 88 , particularly an IL-18 binding molecule which prevents binding of free IL-18 to IL-18 receptor claim 88 , especially free IL-18 binding to IL-18Rα.90. The method of claim 89 , wherein the inhibitor is an IL-18 binding molecule is an IL-18 binding protein (IL-18BP) claim 89 , particularly a human IL-18BP (hIL-18BP) claim 89 , particularly IL-18BP including any functional equivalents or parts thereof claim 89 , particularly an IL-18BP as shown in SEQ ID NO: 7.91. The method of claim 90 , wherein the IL-18BP is a full-length protein or a mutein claim 90 , functional derivative claim 90 , functional fragment claim 90 , biologically active peptide claim 90 , fraction claim 90 , circularly permuted derivative claim 90 , fused protein claim 90 , isoform or a salt thereof.92. An IL-18 specific antibody including any functionally ...

Surgical marker element, surgical referencing unit, and surgical navigation system

The invention relates to a marker element, in particular a medical or surgical marker element, for a referencing unit of a navigation system, which marker element is configured to be reflective to electromagnetic radiation, further comprising a layer comprising a multitude of retroreflective elements. An improved referencing unit and an improved navigation system are also provided.

Storage Tray for a Ladder and Ladder with this Storage Tray

The described apparatus relates to a storage tray for a ladder, in particular a runged stepladder, wherein the storage tray has at least one compartment into which objects can be placed, and has a first receiver for a first element of a buckle closure, which can be attached on the storage tray.

Humanized Antibody

The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies that specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies of the present invention are particularly useful for the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system, particularly associated with amyloid-beta-related pathological abnormalities/changes in the tissues of the visual system. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. A method for reducing the plaque load or reducing the amount of plaques in the retinal ganglion cell layer of a subject suffering from an ocular disease associated with pathological abnormalities/changes in the tissues of the visual system , or (ii) decreasing the total amount of soluble amyloid-β in the retinal ganglion cell layer of a human subject suffering from an ocular disease associated with pathological abnormalities/changes in the tissues of the visual system , wherein the ocular disease is glaucoma or a primary retinal degeneration other than macular degeneration , said method comprising administering to the subject a pharmaceutical composition comprising a humanized antibody or a fragment thereof that binds to beta-amyloid , wherein the humanized antibody or fragment thereof comprises:(i) a heavy chain variable region (“HCVR”) comprising an HCVR complementarity determining region (“CDR”) 1 comprising the amino acid sequence of SEQ ID NO: 1, an HCVR CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and an HCVR CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (“LCVR”) comprising an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 12; or(ii) an LCVR comprising an LCVR CDR1 comprising the amino acid sequence of SEQ ID NO: 4, an LCVR CDR2 comprising the amino acid sequence of SEQ ID NO: ...

Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines

The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical compositions comprising an antigenic peptide, particularly an antigenic phopho-peptide mimicking a major pathological phosphor-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease. 197-. (canceled)98. An isolated antibody , including a functionally equivalent antibody or a functional part thereof that binds the pathological protein tau-conformer or those parts of the conformer causing the pathological properties of said conformer with an affinity that is at least 40% , particularly at least 50% , particularly at least 60% , particularly at least 70% , particularly at least 80% , particularly at least 90% , particularly at least 95% and up to 100% higher than the binding affinity for the non-pathological tau conformer.99. The antibody of claim 98 , which binds specifically to neurofibrillar tangles (NFTs) and neuropil threads in human Alzheimer's Disease brains.100. The antibody of that binds to an epitope on the tau protein claim 98 , or to a combination of epitopes specific to a pathological protein tau-conformer as represented by or comprised in a peptide sequence selected from the group of sequences as given in SEQ ID NO: 2 claim 98 , SEQ ID NO: 3 claim 98 , SEQ ID NO: 4 claim 98 , SEQ ID NO: 5 claim 98 , SEQ ID NO: 6 claim 98 , SEQ ID NO: 7 claim 98 , SEQ ID NO: 8 claim 98 , and SEQ ID NO: 9 and variant fragments thereof.101. The antibody of obtainable by immunizing a suitable animal with an antigenic peptide having an amino acid sequence as given in SEQ ID NO: 2 claim 100 , SEQ ID NO: 3 claim 100 , SEQ ID NO: 4 claim 100 , SEQ ID NO: 5 claim 100 , SEQ ID NO: 6 claim 100 , SEQ ID NO: 7 claim 100 , SEQ ID NO: 8 claim 100 ...

HUMANIZED ANTIBODY

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. 1152.-. (canceled)153. An artificial hybrid antibody comprising two different heavy/light chain pairs and two different binding sites , or fragment thereof , wherein a first heavy/light chain pair is capable of specifically binding beta-amyloid and comprises:(A) (i) a humanized light chain comprising the amino acid sequence of SEQ ID NO: 13; and (ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16; or(B) (i) a humanized light chain comprising the amino acid sequence of SEQ ID NO: 13; and (ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16 lacking the C-terminal Lys at position 439; or '(ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO:', '(C) (i) a humanized light chain comprising a light chain variable region (LCVR), wherein the LCVR comprises human-derived light chain framework regions, the amino acid sequence of SEQ ID NO: 4 representing complementarity determining region (CDR)1 of the LCVR, the amino acid sequence of SEQ ID NO: 5, the amino acid RVSNRFS, or the amino acid sequence KVSSRFS, representing CDR2 of the LCVR, and the amino acid sequence of SEQ ID NO: 6 representing CDR3 of the LCVR; and'}16 lacking the C-terminal Lys at position 439.154. A nucleic acid molecule comprising a nucleotide sequence encoding the artificial hybrid antibody or fragment thereof according to .155. An expression vector comprising the nucleic acid molecule of .156. A cell comprising the expression vector of .157. A method for preventing claim 153 , treating or alleviating the effects of amyloidosis claim 153 , a group of diseases and disorders associated with amyloid plaque formation in a subject claim 153 , comprising ...

METHOD OF SAFE ADMINISTRATION OF PHOSPHORYLATED TAU PEPTIDE VACCINE

Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome. 1. A method of inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in a human subject in need thereof , comprising administering to the subject an effective amount of liposomes comprising a toll-like receptor 4 agonist and a Tau phosphopeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:3 and SEQ ID NO:5 to SEQ ID NO:12 , wherein the Tau phosphopeptide is administered at an amount of about 25 nmoles to about 750 nmoles per dose , and the Tau phosphopeptide is presented on the surface of the liposome.2. The method of claim 1 , wherein the Tau phosphopeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:27 to SEQ ID NO:29 and SEQ ID NO:31 to SEQ ID NO:38.3. The method of claim 1 , wherein the effective amount of liposomes comprises 100 μg to 2500 μg per dose of the Tau phosphopeptide.4. The method of claim 3 , wherein the effective amount of liposomes comprises 300 μg per dose claim 3 , 900 μg per dose claim 3 , 1800 μg per dose claim 3 , or 2400 μg per dose of the Tau phosphopeptide.5. The method of claim 1 , wherein the liposomes are administered subcutaneously.6. The method of claim 1 , wherein the liposomes are administered intramuscularly.7. The method of claim 1 , further comprising administering to the subject a second dose of the effective amount of liposomes 1 to 24 weeks after the initial administration.8. The method of claim 1 , wherein the liposome further comprises a helper T-cell epitope and a lipidated CpG oligonucleotide.9. The method of claim 8 , wherein the lipidated CpG oligonucleotide has a nucleotide sequence selected from ...

Resonant dc-dc converter

A resonant DC-DC converter includes an inverter circuit, a rectifier circuit and a transformer unit. The inverter circuit is connected to a first terminal of the transformer unit, and the rectifier circuit is connected to a second terminal of the transformer unit. The first and second terminals are galvanically isolated from one another by a first transformer. The transformer unit is configured to adapt a transformation ratio of the transformer unit. The transformer unit has an energy transmission path which includes an inverter and a second transformer, with an input of the energy transmission path being arranged parallel to a primary side of the first transformer and an output of the energy transmission path being arranged in series with the secondary side of the first transformer.

HUMANIZED ANTIBODY

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. 1152.-. (canceled)153. An artificial hybrid antibody comprising two different heavy/light chain pairs and two different binding sites , or fragment thereof , wherein a first heavy/light chain pair is capable of specifically binding beta-amyloid and comprises:(A) (i) a humanized light chain comprising the amino acid sequence of SEQ ID NO: 13; and (ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16; or(B) (i) a humanized light chain comprising the amino acid sequence of SEQ ID NO: 13; and (ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16 lacking the C-terminal Lys at position 439; or '(ii) a humanized heavy chain comprising the amino acid sequence of SEQ ID NO: 16 lacking the C-terminal Lys at position 439.', '(C) (i) a humanized light chain comprising a light chain variable region (LCVR), wherein the LCVR comprises human-derived light chain framework regions, the amino acid sequence of SEQ ID NO: 4 representing complementarity determining region (CDR)1 of the LCVR, the amino acid sequence of SEQ ID NO: 5, the amino acid RVSNRFS, or the amino acid sequence KVSSRFS, representing CDR2 of the LCVR, and the amino acid sequence of SEQ ID NO: 6 representing CDR3 of the LCVR; and'}154. A nucleic acid molecule comprising a nucleotide sequence encoding the artificial hybrid antibody or fragment thereof according to .155. An expression vector comprising the nucleic acid molecule of .156. A cell comprising the expression vector of .157. A method for preventing claim 153 , treating or alleviating the effects of amyloidosis claim 153 , a group of diseases and disorders associated with amyloid plaque formation in a subject claim 153 , comprising ...

IL-18 BINDING PROTEIN (IL-18BP) IN INFLAMMATORY DISEASES

The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications. 1. A method for treating an IL-18 associated disease or disorder in a population of subjects diagnosed of having abnormal levels of free IL-18 and/or an abnormal ratio of free IL-18/IL-18 binding protein (IL-18BP) in the body fluids compared to the levels in the body fluids of a healthy control subject , or of having a predisposition to develop such a disease or disorder , comprising administering to said subject a therapeutically or prophylactically effective amount of an IL-18 inhibitor.2. A method for treating an IL-18 associated disease or disorder in a population of subjects diagnosed of having abnormal levels of free IL-18 and/or an abnormal ratio of free IL-18/IL-18 binding protein (IL-18BP) in the body fluids compared to the levels in the body fluids of a healthy control subject , or of having a predisposition to develop such a disease or disorder , comprising administering to said subject a therapeutically or prophylactically effective amount of an IL-18 inhibitor , wherein the level of free IL-18 in the body fluids of the subjects has been determined by an immunoassay.3. The method of claim 2 , wherein the immunoassay comprises an IL-18BP or a functional equivalent or a functional part thereof as the capturing molecule.4. The method of claim 3 , wherein the IL-18BP is a human IL-18BP (hIL-18BP).5. The method of claim 4 , wherein the hIL-18BP is a recombinant hIL-18BP.6. The method of claim 3 , wherein the IL-18BP is an isoform of IL-18BP.7. The method of claim 1 , wherein the abnormal levels of free IL-18 and/or abnormal ratio of free IL-18/IL-18BP in the body fluids compared to the levels in the body fluids of a healthy control subject have been ...

Sensor system for buried waste containment sites

A sensor system for a buried waste containment site having a bottom wall barrier and sidewall barriers, for containing hazardous waste. The sensor system includes one or more sensor devices disposed in one or more of the barriers for detecting a physical parameter either of the barrier itself or of the physical condition of the surrounding soils and buried waste, and for producing a signal representing the physical parameter detected. Also included is a signal processor for receiving signals produced by the sensor device and for developing information identifying the physical parameter detected, either for sounding an alarm, displaying a graphic representation of a physical parameter detected on a viewing screen and/or a hard copy printout. The sensor devices may be deployed in or adjacent the barriers at the same time the barriers are deployed and may be adapted to detect strain or cracking in the barriers, leakage of radiation through the barriers, the presence and leaking through the barriers of volatile organic compounds, or similar physical conditions.

IMPROVED SWITCH LAYER REACTOR SYSTEM

Spindle drive for an adjusting element of a motor vehicle

Die Erfindung betrifft einen Spindelantrieb für ein Verstellelement (1) eines Kraftfahrzeugs, wobei eine Antriebseinheit (3) mit einem materialeinheitlich ausgebildeten Antriebseinheitsgehäuse (4), wobei der Spindelantrieb (1) zwei gegeneinander laufende Antriebsabschnitte (9, 10) aufweist, wobei der spindelseitige Antriebsabschnitt (11) ein materialeinheitlich ausgebildetes Torsionsrohr (16) mit einem Eingriffsabschnitt (16a) aufweist und wobei die Spindelmutter (14) mit dem Eingriffsabschnitt (16a) zur Ausbildung einer Drehmomentstütze drehfest, aber axialverschieblich in Eingriff steht. Es wird vorgeschlagen, dass das Torsionsrohr (16) einen Befestigungsabschnitt (16b) aufweist, der drehfest und axialfest am Antriebseinheitsgehäuse (4) befestigt ist. The invention relates to a spindle drive for an adjusting element (1) of a motor vehicle, wherein a drive unit (3) with a unitary drive unit housing (4), wherein the spindle drive (1) has two mutually running drive sections (9, 10), wherein the spindle-side drive section (11) has a material-uniform torsion tube (16) with an engaging portion (16a) and wherein the spindle nut (14) with the engaging portion (16a) for forming a torque arm rotationally fixed, but axially displaceable engaged. It is proposed that the torsion tube (16) has a fastening section (16b), which is fastened in a torque-proof and axially fixed manner to the drive unit housing (4).

HUMANIZED ANTIBODIES AGAINST AMYLOID β

【課題】アルツハイマー病などのアミロイドタンパク質と関連する一群の障害および異常である、アミロイドーシスを含むアミロイドもしくはアミロイド様タンパク質によって引き起こされるかまたはアミロイドもしくはアミロイド様タンパク質と関連する疾患および障害の処置における治療的および診断的使用のための方法および組成物を提供する。【解決手段】β-アミロイドタンパク質上の少なくとも1つのエピトープに特異的に結合する、キメラ抗体もしくはその断片またはヒト化抗体もしくはその断片。前記抗体をコードするヌクレオチド配列を含む、核酸分子。前記抗体を治療的有効量で投与する工程を含む、方法。患者におけるアミロイド関連の疾患または状態の診断の方法。【選択図】なし

CHEMERIC OR HUMANIZED ANTIBODY, OR FRAGMENTS OF THEM, WHICH SPECIFICALLY ADHER TO AT LEAST AN EPITHOPE IN THE BETA-AMYLOID PROTEIN; NUCLEIC ACID MOLECULA THAT CODIFIES IT; COMPOSITION THAT UNDERSTANDS IT; YOUR USE TO TREAT NURSING

monoclonal antibody, light chain and heavy chain variable regions, isolated cdr, polynucleotide, therapeutic composition, methods for treating disease and disorder, for producing an antibody, for treating or alleviating the effects of disease and disorder, for reducing plaque burden in an individual's brain, to reduce the amount of plaque in an individual's brain, to decrease the total amount of soluble spruce in an individual's brain, to retain or increase an individual's cognitive memory capacity, to diagnose from or to diagnose a predisposition to an amyloid-associated disease or condition in a patient, to determine the extent of amyloidogenic plaque burden in an individual's tissue, to monitor minimal residual disease in an individual, and to predict an individual's responsiveness, cell line , test kit, epitope fir

pharmaceutical composition, and methods for reducing plaque burden and plaque quantity in an individual's retinal ganglion cell layer, to prevent, treat and / or alleviate the effects of an eye disease, to diagnose an eye disease and a predisposition to an eye disease, to monitor eye disease, to predict a patient's responsiveness, and to retain or decrease eye pressure in an individual's eyes

Humanized antibody

Ovaj izum odnosi se na kimerno i humanizirano protutijelo, te na postupke i pripravke namijenjene upotrebi u terapiji i dijagnostici kod liječenja amiloidoze, koja je skupina poremećaja i nenormalnosti uzrokovanih amiloidnim proteinom, poput Alzheimerove bolesti. The present invention relates to a chimeric and humanized antibody, and to methods and compositions for use in therapy and diagnosis in the treatment of amyloidosis, which is a group of disorders and abnormalities caused by an amyloid protein, such as Alzheimer's disease.

Apparatus for measuring physical and/or chemical variables of liquids or gases

An apparatus for measuring physical and/or chemical variables of liquids or gases in pipelines is described in which at least one sensor is arranged in a connecting piece branching from the pipe. The sensor (3) is located in the area of a tangential plane (5) to the pipe cross-section and is fastened there in a sealing manner while avoiding gaps. The sensor (3) preferably rests in the area of the tangential plane (5) on a collar (9) whose edge (10) directed towards the interior of the pipe is rounded off or bevelled. Dead spaces are thereby avoided and corners in which deposits or micro-organisms could collect are prevented. <IMAGE>

Cable chain return system and associated methods

Disclosed is a cable chain return system 100 that includes a spring 170 for assisting folding and organization of a cable chain 110 . When a customer replaceable unit (CRU) 210 is extended from a chassis 140 to gain access to connectors on the back of the CRU 210 , the cable chain 110 is extended. When the CRU 210 is moved back into the chassis 140 , a plurality of folding curves 130 organize the cable chain 110 , and cables 118 therein, without damaging the cables 118 or inhibiting positioning of the CRU 210 in the chassis 140 . One of these curves 130 is initiated by the spring 170 and therefore aids in returning and organizing of the cable chain 110.

Cable chain return system and associated methods

Disclosed is a cable chain return system 100 that includes a spring 170 for assisting folding and organization of a cable chain 110 . When a customer replaceable unit (CRU) 210 is extended from a chassis 140 to gain access to connectors on the back of the CRU 210 , the cable chain 110 is extended. When the CRU 210 is moved back into the chassis 140 , a plurality of folding curves 130 organize the cable chain 110 , and cables 118 therein, without damaging the cables 118 or inhibiting positioning of the CRU 210 in the chassis 140 . One of these curves 130 is initiated by the spring 170 and therefore aids in returning and organizing of the cable chain 110.

Sunscreen concentrate with organic micropigments

Verfahren zur Herstellung einer kosmetischen Zubereitung, dadurch gekennzeichnet, dass eine O/W-Emulsion, enthaltend DOLLAR A a) eine wässrige Phase, DOLLAR A b) eine Ölphase, DOLLAR A c) pigmentäre UV-Lichtschutzfilter und DOLLAR A d) wasserlösliche Polymere, DOLLAR A neben gegebenenfalls weiteren kosmetischen und/oder dermatologischen Wirk-, Hilfs- und Zusatzstoffen, durch Sprühtrocknung, Gefriertrocknung und/oder Walzentrocknung getrocknet wird. Process for the preparation of a cosmetic preparation, characterized in that an O / W emulsion containing DOLLAR A a) an aqueous phase, DOLLAR A b) an oil phase, DOLLAR A c) pigmentary UV light protection filters and DOLLAR A d) water-soluble polymers, DOLLAR A in addition to optionally other cosmetic and / or dermatological active ingredients, excipients and additives, dried by spray drying, freeze drying and / or drum drying.

Roller Assembly System and Method for Installation

Provided is a roller assembly for cargo handling on a deck having at least one tie down ring. The assembly comprises a roller tray comprising a support frame and a plurality of rollers mounted on or in the support frame, and a bracket coupled to the roller tray. The bracket comprises a coupling portion used to couple the bracket to the support frame, and a securing portion having a slot extending therethrough, the securing portion used to secure the roller assembly to the deck. The roller assembly is secured to the deck when the tie down ring is inserted through the slot and rotated.

A method of making a coating having markings on a surface or part of a surface of an article

Verfahren zur Herstellung einer Beschichtung auf einer Oberfläche oder einem Teil einer Oberfläche eines Gegenstandes, aufweisend a) Aufbringen einer ersten Schicht, aufweisend ein erstes Polymer, auf die zu beschichtende Oberfläche oder den zu beschichtenden Teil der Oberfläche, wobei die erste Schicht ein lasersensitives Pigment und/oder lasersensitives Färbemittel aufweist, b) Bestrahlen der ersten Schicht zumindest stellen- oder abschnittsweise, mit einem Laserstrahl, sodass auf/in der ersten Schicht eine Lasermarkierung erzeugt wird, c) Aufbringen einer zweiten Schicht, aufweisend ein zweites Polymer auf die erste Schicht, wobei das zweite Polymer eine Deckschicht ausbildet, durch welche die Lasermarkierung sichtbar ist, Beschichtung, die nach dem Verfahren erhältlich ist, und Gegenstand mit einer solchen Beschichtung. A method of forming a coating on a surface or portion of a surface of an article, comprising a) applying a first layer comprising a first polymer to the surface to be coated or the portion of the surface to be coated, the first layer comprising a laser sensitive pigment and b) irradiating the first layer at least in sections or sections, with a laser beam, so that a laser marking is produced on / in the first layer, c) applying a second layer comprising a second polymer to the first layer, wherein the second polymer forms a cover layer through which the laser marking is visible, coating obtainable by the method, and article having such a coating.

Nutrient contg. soils prepn. - by granulating inorganic and organic waste components with liq. that contains plant nutrients.

The prepn. comprises, partially or completely granulating the organic and inorganic components with a liq. that contains plant nutrients, using a roll agglomeration technique. USE/ADVANTAGE - The process utilises various waste prods. such as debris from building, liq. manure, old paper, etc. and avoids, e.g. contamination of ground water, unpleasant smell, health risks etc., previously associated with the removal of such waste prods.. The granulation ensures that the liqs. used, most of which have very strong unpleasant smells are bonded so that the aroma components are also bonded and the nutrient components are fixed.

AQUEOUS SODIUM CROMOGLYCATE COMPOSITION

L'INVENTION CONCERNE L'INDUSTRIE PHARMACEUTIQUE ELLA A POUR OBJET UNE COMPOSITION AQUEUSE DE CROMOGLYCATE DE SODIUM AYANT UNE VISCOSITE DE 2 A 300 MPA.S QUI CONTIENT DE PREFERENCE DE L'HYDROXYPROPYLMETHYLCELLULOSE. DANS UNE FORME DE REALISATION PREFEREE, L'HYDROXYPROPYLMETHYLCELLULOSE CONTIENT 20 A 30 DE RADICAUX METHOXY ET 4 A 12 DE RADICAUX HYDROXYPROPOXY ET A UNE TEMPERATURE DE GELIFICATION EN MILIEU AQUEUX ENTRE 45 ET 90C. LA COMPOSITION EST PREFEREE POUR LE TRAITEMENT DES AFFECTIONS ALLERGIQUES DE L'OEIL ET DU NEZ. THE INVENTION CONCERNS THE PHARMACEUTICAL INDUSTRY ELLA'S OBJECT IS AN AQUEOUS COMPOSITION OF SODIUM CROMOGLYCATE HAVING A VISCOSITY OF 2 TO 300 MPA.S WHICH PREFERABLY CONTAINS HYDROXYPROPYLMETHYLCELLULOSE. IN A PREFERRED EMBODIMENT, HYDROXYPROPYLMETHYLCELLULOSE CONTAINS 20 TO 30 METHOXY RADICALS AND 4 TO 12 HYDROXYPROPOXY RADICALS AND HAS AN AQUEOUS GELING TEMPERATURE BETWEEN 45 AND 90C. THE COMPOSITION IS PREFERRED FOR THE TREATMENT OF ALLERGIC DISORDERS OF THE EYE AND NOSE.

Motor starting switch

Ecg based future atrial fibrillation predictor systems and methods

A method and system for predicting the likelihood that a patient will suffer from atrial fibrillation is provided. The method includes receiving electrocardiogram data associated with the patient, providing at least a portion of the electrocardiogram data to a trained model, receiving a risk score indicative of the likelihood the patient will suffer from atrial fibrillation within a predetermined period of time from when the electrocardiogram data was generated, and outputting the risk score to at least one of a memory or a display for viewing by a medical practitioner or healthcare administrator. The system includes at least one processor executing instructions to carry out the steps of the method.

Diamines and their preparation

Sodium cromoglycate formulation

There is described an aqueous formulation of sodium cromoglycate which has a viscosity of from 2 to 300 mPa.s. The formulation preferably contains hydroxypropyl methylcellulose. There is also described a method of treating allergic conditions of the eye and nose using the formulation.

PROCESS FOR THE MANUFACTURE OF A MEDICAL DRESSING

Procédé pour la fabrication d'un pansement médical polyvalent offrant une protection suffisante contre les bactéries et présentant de bonnes propriétés mécaniques et lyophiles. Une feuille de mousse de polyuréthane à alvéoles ouverts non comprimée de 0,5 à 10 mm d'épaisseur est ramollie à l'une de ses surfaces, sans décomposition thermique, jusqu'à obtention du pouvoir adhésif voulu et est reliée ensuite, de manière perméable aux gaz et à la vapeur d'eau, à une feuille de mousse de polyuréthane souple comprimée irréversiblement de façon que son épaisseur soit réduite de 2 à 30 fois, l'ensemble ainsi obtenu étant ensuite nettoyé par voie physique et/ou chimique. L'invention est applicable en particulier au traitement de brûlures et analogues. Process for the manufacture of a multipurpose medical dressing providing sufficient protection against bacteria and exhibiting good mechanical and lyophilic properties. A sheet of uncompressed open cell polyurethane foam 0.5 to 10 mm thick is softened at one of its surfaces, without thermal decomposition, until the desired adhesive power is obtained and is then bonded in such a manner. permeable to gas and to water vapor, to a sheet of flexible polyurethane foam irreversibly compressed so that its thickness is reduced from 2 to 30 times, the assembly thus obtained being then cleaned by physical and / or chemical means. The invention is particularly applicable to the treatment of burns and the like.

waste collectors

Apparatus for the wet treatment of strip-shaped photographic support

Production of storage-stable, homogeneous detergent optionally containing heavy components by agglomeration in a rotatable mixer with anionic surfactant introduced in acid form

Production of a detergent granulate comprises agglomerating a solid containing appropriate ingredients together with a granulating fluid in a rotatable container of specified construction, at least part of the anionic surfactant present in the product having been introduced in acid form into the process. Production of a detergent granulate comprises agglomerating a solid containing appropriate ingredients together with a granulating fluid in a rotatable container of specified construction, at least part of the anionic surfactant present in the product having been introduced in acid form into the process. The rotatable container is without a mixing device and is divided into a mixing zone and a post-mixing zone, there being an impact strip fixed to a front plate and from there traversing the whole of the mixing zone and optionally reaching into the post-mixing zone.

Pig bristle remover and scouring trough

Pig bristle remover operates in conjunction with a conventional scouring trough and works on a three phase principle. The first consists of a frame housing two flexible rubber or plastics scrapers mounted on drums, the second incorporates a gas burner to singe the pig right round and the third phase is formed from a rotating brush drum.

Active substance-containing foam and method and composition for its production

Es wird ein Verfahren zur Herstellung eines wirkstoffhaltigen Schaums beschrieben, wobei der wirkstoffhaltige Schaum ein Protein sowie ein Fett und/oder ein Wachses umfasst. Das Verfahren umfasst folgende Schritte: A) Bereitstellung der Fettsäureesterkomponente und der Proteinkomponente, wobei – die Fettsäureesterkomponente und/oder die Proteinkomponente einen schaumstabilisierenden Bestandteil enthalten – zumindest die Fettsäureesterkomponente im Wesentlichen biogenen Ursprungs ist, – die Proteinkomponente und die Fettsäureesterkomponente in einem Gewichtsverhältnis von 1:10 bis 10:1 vorliegen, – in die Fettsäureesterkomponente mindestens einen pharmazeutischer und/oder kosmetischer Wirkstoff eingebracht ist oder eingebracht wird, B) Mischen der Proteinkomponente und der Fettsäureesterkomponente gegebenenfalls, so dass enthaltenes Wasser und die summierten Anteile von Proteinkomponente und Fettsäureesterkomponente in einem Gewichtsverhältnis von 1:1 bis 20:1 vorliegen und wobei der Anteil der Fettsäureesterkomponente im entstandenen Gemisch größer 3 Gew.-% ist, C) Einbringen eines Gases in das nach Schritt B) erhaltene Gemisch, so dass ein Schaum entsteht. A method for producing an active ingredient-containing foam is described, the active ingredient-containing foam comprising a protein and a fat and / or a wax. The method comprises the following steps: A) Provision of the fatty acid ester component and the protein component, wherein - the fatty acid ester component and / or the protein component contain a foam-stabilizing component - at least the fatty acid ester component is of essentially biogenic origin, - the protein component and the fatty acid ester component in a weight ratio of 1: 10 to 10: 1 are present, - at least one pharmaceutical and / or cosmetic active ingredient is or is being introduced into the fatty acid ester component, B) if appropriate, mixing the protein component and the fatty acid ester component so that the water contained and the summed ...

Method and apparatus for traffic surveillance

Method for determining the exposure time of a photographic copy material and device for carrying out the method

Thermochemical ablation system using heat from delivery of electrophiles

Thermochemical ablation techniques may provide abla-tion of bodily tissue using chemical reaction energy. The chemical reac-tion energy is provided by chemical reactions including a highly reac-tive electrophilic reagent provided to a target tissue location. The elec-trophilic agent is injected by a percutaneous fluid delivery cannula or by a percutaneous injection needle.

Artificial Intelligence Based Cardiac Event Predictor Systems and Methods

A method and system for predicting the likelihood that a patient will suffer from a cardiac event is provided. The method includes receiving electrocardiogram data associated with the patient, providing at least a portion of the electrocardiogram data to a trained model, receiving a risk score indicative of the likelihood the patient will suffer from the cardiac event within a predetermined period of time from when the electrocardiogram data was generated, and outputting the risk score to at least one of a memory or a display for viewing by a medical practitioner or healthcare administrator. The system includes at least one processor executing instructions to carry out the steps of the method.

Device for controlling the build-up of bobbins on roving machines

MATRIX OF CEMENT AND PROCEDURE FOR THE OBTAINING.

LA INVENCION SE REFIERE A UN AGLOMERANTE DE CEMENTO Y A SU PRODUCCION VENTAJOSA, EN PARTICULAR PARA CEMENTO ARMADO CON FIBRA DE VIDRIO U HORMIGON, QUE CONSISTE EN UN CEMENTO ESTANDAR O ESPECIAL Y ADITIVOS SOLIDOS O LIQUIDOS PARA AGLOMERAR EL HIDROXIDO CALCICO QUE SE FORMA DURANTE EL PROCESO DE HIDRACION. UN ADITIVO PARTICULARMENTE VENTAJOSO ES EL DIOXIDO DE SILICIO REACTIVO QUE SE RECUPERA DE LOS GASES DE LA COMBUSTION DURANTE LA PRODUCCION DE SILICIO O DE FERROSILICIO, TRAS LO CUAL EL DIOXIDO DE SILICIO SE REDUCE PRIMERO Y EL PRODUCTO DE LA REDUCCION SE OXIDIZA ENTONCES EN AIRE. LA CANTIDAD TOTAL DE ADITIVOS DEBE SER AL MENOS EQUIVALENTE A LA CANTIDAD REQUERIDA NECESARIA, PARA AGLOMERAR EL HIDROXIDO CALCICO TOTAL PRODUCIDO DURANTE LA HIDRACION O PARA PROVOCAR UNA REACCION. LOS OTROS ADITIVOS, APARTE DEL DIOXIDO DE SILICIO REACTIVO SON METACAOLIN, TIERRA DIATOMACEA, PUZOLANA, ESCORIAS DE ALTOS HORNOS Y CENIZA MUY FINA O UNA COMBINACION DE ESTOS. THE INVENTION IS CONCERNING A CEMENT BINDER AND ITS ADVANTAGEFUL PRODUCTION, IN PARTICULAR FOR FIBER-GLASS OR CONCRETE CONCRETE, WHICH CONSISTS OF A STANDARD OR SPECIAL CEMENT AND SOLID ADDITIVES FOR BINDING THE DURATION OF HYDROXIDE AND HYDROXIDE. HYDRATION. A PARTICULARLY ADVANTABLE ADDITIVE IS REACTIVE SILICON DIOXIDE THAT IS RECOVERED FROM COMBUSTION GASES DURING THE PRODUCTION OF SILICON OR FERROSILICE, WHEN THE SILICON DIOXIDE IS REDUCED FIRST AND THE PRODUCT IS REDUCED IN SEX. THE TOTAL AMOUNT OF ADDITIVES MUST BE AT LEAST EQUIVALENT TO THE REQUIRED AMOUNT NECESSARY, TO BIND THE TOTAL CALCIUM HYDROXIDE PRODUCED DURING HYDRATION OR TO CAUSE A REACTION. THE OTHER ADDITIVES, SEPARATE OF THE REACTIVE SILICON DIOXIDE ARE METACAOLIN, DIATOMACEA EARTH, PUZOLANA, HIGH FURNACE SLAGS AND VERY FINE ASH OR A COMBINATION OF THESE.

Automated video content processing

Video content is processed for delivery using an automated process that allows for convenient packaging of encrypted or digital rights management (DRM) protected content in a manner such that the packaged content can be efficiently stored in a content delivery network (CDN) or other content source for subsequent re-use by other media clients without re-packaging, and without excessive storage of unused content data.

Storage tray for a ladder and ladder with this storage tray

A beta 1-42 specific monoclonal antibodies with therapeutic properties.

La presente invención se refiere a una formula humanizada de un anticuerpo obtenible del hibridoma depositado el 1° de diciembre de 2005 bajo el número de acceso DSMA CC2751, o un fragmento del mismo, en donde el anticuerpo es humanizado al insertar regiones determinantes de complementariedad (CDR) del anticuerpo en una estructura humana, en donde la forma humanizada del anticuerpo o el fragmento del mismo se une a ß-amiloide.

Device for controlling the winding structure on roving machines

Spindle drive

A spindle drive for an adjustment element of a motor vehicle, including a tubular drive housing having a first housing pipe, a spindle/spindle nut transmission configured to produce linear drive movements, a first drive connection and a second drive connection configured to discharge the drive movements, the first drive connection forms with one of the transmission components a first drive train component and the second drive connection forms with the other of the transmission components a second drive train component. A housing cover axially closing the drive housing and arranged in an axially secure manner relative to the first drive connection. The first housing pipe arranged in an axially secure manner relative to the first drive connection. A housing collar in a first coupling portion of the spindle drive connected to the first housing pipe and in a second coupling portion coupled to the housing cover.

MEDICAL WOUND ASSOCIATION

Ziel der Erfindung ist es, einen medizinischen Wundverband mit federnder Nachgiebigkeit, definierter Gasdurchlaessigkeit, Schutz gegen Bakterien und guten lyophilen Eigenschaften zu entwickeln. Der medizinische Wundverband soll aus einer Vorder- und Rueckseite aus Polyurethan-Weichschaum bestehen. Die Aufgabe wird dadurch geloest, dass eine offenporige Polyurethan-Weichschaumstoffolie, mit einer Dicke von 1,2 bis 3 mm, auf einer Oberflaeche ohne thermische Zersetzung angeschmolzen wird und mit einer auf das 10- bis 30fache irreversibel verdichteten Polyurethan-Weichschaumstoffolie, mit einer Dicke von 0,1 bis 0,4 mm, gas- und wasserdampfdurchlaessig verbunden wird.

Pharmaceutical composition

Method for producing an inductive sensor

Die Erfindung betrifft ein Verfahren zur Herstellung eines induktiven Sensors, bei welchem auf eine Trägerplatte (7) beidseitig, eine Öffnung der Trägerplatte (7) umschließende Spulen (8, 9) aufgebracht werden und die Trägerplatte (7) mit den Spulen (8, 9) in ein Gehäuse (2) eingeführt wird, wobei eine Hülse (5) durch eine erste Ausnehmung (3) des Gehäuses (2) durch die Öffnung der Trägerplatte (7) hindurch in das Gehäuse (2) eingeführt wird. Um eine haftfeste und temperaturunabhängige Verbindungsstelle zwischen der Hülse und dem Gehäuse zu erreichen, wird die Hülse (5) mit dem Gehäuse (2) verschweißt. The invention relates to a method for producing an inductive sensor, in which coils (8, 9) enclosing an opening of the carrier plate (7) are applied to a carrier plate (7) and the carrier plate (7) is connected to the coils (8, 9 ) is inserted into a housing (2), wherein a sleeve (5) through a first recess (3) of the housing (2) through the opening of the support plate (7) is inserted into the housing (2). In order to achieve an adherent and temperature-independent connection point between the sleeve and the housing, the sleeve (5) with the housing (2) is welded.

Circuit arrangement for controlling an electrical load and method for its operation

Die Erfindung betrifft eine Schaltungsanordnung zur Ansteuerung eines ein- oder mehrphasigen elektrischen Verbrauchers (10), mit einem oder mehreren Leitungsschutzelementen (31, 32, 33), die in einer jeweiligen Phase (L1, L2, L3) zwischen zugeordneten Netzanschlüssen und dem Verbraucher (10) angeordnet sind, und mit einer Einrichtung (20) zur Steuerung und/oder Ein-/Ausschaltstrombegrenzung des Verbrauchers (10), welche zwischen dem Verbraucher (10) und dem oder den Leitungsschutzelementen (31, 32, 33) angeordnet ist. Ein Überwachungsmittel (40) ist zur Überwachung der Schaltungsanordnung auf das Vorliegen eines Fehlers vorgesehen. Weiter sind ein oder mehrere, steuerbare Schaltelemente (50, 51) vorgesehen, wobei ein jeweiliges Schaltelement (50, 51) zwischen einer Phase (L1, L2, L3) und einer anderen Phase (L1, L2, L3) oder einem Rückleiter verschaltet ist. Das Überwachungsmittel (40) schaltet bei einem detektieren Fehler zumindest eines der Schaltelemente (50, 51) leitend, um ein Auslösen des oder der Leitungsschutzelemente (31, 32, 33) zu erzwingen. The invention relates to a circuit arrangement for controlling a single-phase or multi-phase electrical load (10), having one or more line protection elements (31, 32, 33) which are connected in a respective phase (L1, L2, L3) between associated network connections and the consumer ( 10), and with a device (20) for controlling and / or on / off current limiting of the consumer (10), which between the consumer (10) and the one or more line protection elements (31, 32, 33) is arranged. A monitoring means (40) is provided for monitoring the circuit for the presence of a fault. Further, one or more controllable switching elements (50, 51) are provided, wherein a respective switching element (50, 51) between a phase (L1, L2, L3) and another phase (L1, L2, L3) or a return conductor is connected , The monitoring means (40) turns on a detected error of at least one of the switching elements (50, 51) conductive to force ...

Directional coupler, consisting of an outer screen and two inner conductors arranged inside this screen

Diagnostic device for photovoltaic module, has measuring unit measuring leakage current of modules at grounded terminal, where leakage current is caused by signal due to capacitance increase as sequence of damage of modules

Erfindungsgemäß wird eine Diagnoseeinrichtung für ein Fotovoltaikmodul (1, 2) mit einer Messeinrichtung (7) zur Messung eines Ableitstroms (If) und ein zugehöriges Verfahren vorgeschlagen. Der Ableitstroms (If) tritt aufgrund einer Kapazitätsänderung als Folge einer Schädigung des Fotovoltaikmoduls (1, 2) auf.

METHOD OF STRUCTURING

Process for the continuous manufacture of fibrous concrete slabs

A method for the continuous production of plates and/or shaped bodies of fibre reinforced hydraulic setting masses is described in which the mass is provided in a predetermined thickness over the entire width of the plate to be produced, on a substrate continuously moved by a belt. Fibre cuttings from a cutting device are dispersed in a desired distribution onto the surface of the mass moving with the substrate and these are subsequently incorporated into the mass by a tool acting uniformly over the entire width of the mass. The raw plate can be further processed in its still deformable condition and brought into a desired final shape.

Blank and intermediate article for the production of a dental prosthetic item and process for the production thereof

The invention relates to a blank for the production of a dental prosthesis. The blank has a frame structure with open-pored cavities. Other objects of the invention are a dental prosthesis produced from a blank and a method for the production of a blank and/or dental prosthesis.

cassette

Converter comprising redundant switch-fuse combinations and method for selective triggering of the fuse in the event of switch failure

The invention relates to a converter (1) comprising an intermediate circuit (3) for providing a DC voltage (10) between a positive conductor (11) and a negative conductor (12), a phase conductor (8, 9) for receiving and/or output of an AC voltage, and a half-bridge circuit (17) comprising a first switch arrangement (18) for connecting the positive conductor (11) to the phase conductor (8, 9) and a second switch arrangement (19) for connecting the negative conductor (12) to the phase conductor (8, 9). In case of a defect of a semiconductor switch (20, 21) of the converter (1), the converter (1) is to be able to protect itself and continue to operate. For this purpose, the first switch arrangement (18) and the second switch arrangement (19) respectively have a parallel connection made of multiple switching branches (Z) and, in each switching branch (Z), one of the semiconductor switches (20, 21) is provided with an intrinsic safety fuse (22) switched in series to the contact gap of the semiconductor switch (20, 21).

METHOD FOR PRODUCING POLYURETHANE SOFT FOAMS

DAS ERFINDUNGSGEMAESSE VERFAHREN WIRD ZUR HERSTELLUNG VON POLYURETHANWEICHSCHAUMSTOFFEN ANGEWENDET, DIE IN DER MOEBELINDUSTRIE UND IM TRANSPORTWESEN VORZUGSWEISE FUER POLSTERUNGEN EINGESETZT WERDEN. ZIEL UND AUFGABE DER ERFINDUNG BESTEHEN IN DER SCHAFFUNG EINES OEKONOMISCHEN VERFAHRENS ZUR HERSTELLUNG VON POLYURETHAN-WEICHSCHAUMSTOFFEN BEI EINSATZ EINER SPEZIELLEN ISOCYANATKOMPONENTE. ERFINDUNGSGEMAESS WIRD DIE AUFGABE DADURCH GELOEST, DASS ALS URETHANMODIFIZIERTES AROMATISCHES POLYISOCYANAT EINE ISOCYANATKOMPONENTE EINGESETZT WIRD, DIE EIN UMSETZUNGSPRODUKT AUS EINEM PHOSGENIERTEN ANILIN-FORMALDEHYG-KONDENSAT, DAS 60 % BIS 75 % DIPHENYLMETHANDIISOCYANAT ENTHAELT UND AUS MINDESTENS 95 % DES 4,4'-ISOMEREN BESTEHT, UND AUS EINEM ODER GEGEBENENFALLS MEHREREN POLYOXYALKYLENPOLYOLEN, DIE IM MOLEKUEL 2 BIS 3 OH-GRUPPEN ENTHALTEN UND EIN MOLEKULARGEWICHT GROESSER 2000, VORZUGSWEISE 3000 BIS 6500, AUFWEISEN, IST. THE INVENTION METHOD IS USED FOR THE MANUFACTURE OF POLYURETHANE FOAMING FUELS USED PREFERABLY FOR PADDING IN THE MOEBEL INDUSTRY AND TRANSPORT. THE OBJECT AND OBJECT OF THE INVENTION ARE TO OBTAIN AN ECONOMIC PROCEDURE FOR THE PREPARATION OF POLYURETHANE SOFT FOAMS USING A SPECIAL ISOCYANATE COMPONENT. ERFINDUNGSGEMAESS, the object is achieved in that ALS urethane-modified aromatic polyisocyanate an isocyanate IS USED BY A reaction product of a phosgenated ANILINE FORMALDEHYG-condensate from 60% to 75% of diphenylmethane diisocyanate and at least 95% of the 4,4'-isomer IS , AND OF ONE OR, IF APPLICABLE, MULTIPLE POLYOXYALKYLENE POLYOLS CONTAINING 2 TO 3 OH GROUPS IN THE MOLECULAR AND A MOLECULAR WEIGHT OF GREATER 2000, PREFERABLY 3000 TO 6500.

Transparent copolyamides and their use in producing moulded objects

Automated video content processing

Video content is processed for delivery using an automated process that allows for convenient packaging of encrypted or digital rights management (DRM) protected content in a manner such that the packaged content can be efficiently stored in a content delivery network (CDN) or other content source for subsequent re-use by other media clients without re-packaging, and without excessive storage of unused content data.

Method and device for controlling the package structure on roving machines

Fastening means, in particular for bellows, with a male and a female end portion

Die Aufgabe der Erfindung ist es, ein Befestigungsmittel, insbesondere für Bälge, mit einem männlichen und einem hierzu komplementären weiblichen Endabschnitt als auch dessen Verwendung zur Befestigung von Bälgen auf Gelenkgehäusen und/oder Wellen zur Verfügung zu stellen, welches ein verbessertes Schließverhalten aufweist. The object of the invention is to provide a fastening means, in particular for bellows, with a male and a female end portion complementary thereto as well as its use for attachment of bellows on joint housings and / or waves available, which has an improved closing behavior.

Spindle drive for an adjusting element of a motor vehicle

The invention relates to a spindle drive for an adjusting element (1) of a motor vehicle, wherein a drive unit (3) having a material-uniform drive unit housing (4) is provided, wherein the spindle drive (1) has two drive sections (9, 10) that move relative to each other, wherein the spindle-side drive section (11) has a material-uniform torsion tube (16) having an engagement section (16a) and wherein the spindle nut (14) is engaged with the engagement section (16a) in a rotationally fixed but axially movable manner in order to form a torque support. According to the invention, the torsion tube (16) has a fastening section (16b), which is fastened to the drive unit housing (4) in a rotationally fixed and axially fixed manner.

METHOD AND DEVICE FOR THE CONTINUOUS PREPARATION OF 3 (N, N-DIMETHYLAMINO) PROPIONITRIL

Die Erfindung betrifft ein Verfahren und eine Vorrichtung zur kontinuierlichen Herstellung von 3(N,N-Dimethylamino)propionitril durch Addition von Dimethylamin an Acrylnitril, das als Katalysator und Stabilisator einsetzbar ist. Erfindungsgemäß wird di ese Additionsreaktion in einem Rohrreaktor, welcher aus Mischkammern, Rohrsektionen und ggf. Rohstoffzwischendosierungen besteht, durchgeführt. Die Reaktionskomponente werden stufenweise vermischt und über die gesamte Reaktorlänge stufenweise zur Reaktion gebracht.

Processes for obtaining microbial oil from microbial cells

Disclosed herein are processes for obtaining a microbial oil comprising one or more polyunsaturated fatty acids (PUFAs) from one or more microbial cells by lysing the cells to form a lysed cell composition, treating the lysed cell composition to form an oil-containing emulsion and then recovering the oil from the oil-containing emulsion. Further disclosed herein is microbial oil comprising one or more PUFAs that is recovered from microbial cells by at least one process described herein.

Frozen dessert containing lactic acid bacteria and fermentable fiber

Method of removing nitrogen oxides from the exhaust gas of a lean-burn internal combustion engine and exhaust-gas purification system therefor

The present invention relates to a method of removing nitrogen oxides from the exhaust gas of a lean-burn internal combustion engine by selective catalytic reduction (SCR) using ammonia. The exhaust gas is routed first over a platinum-containing pre-catalyst and then over an SCR catalyst. The ammonia needed for the selective catalytic reduction is added to the exhaust gas upstream of the pre-catalyst at an exhaust-gas temperature below 250° C., while it is supplied to the exhaust gas between the pre-catalyst and the SCR catalyst at an exhaust gas temperature above 150° C. By adopting this procedure, a very large temperature range for the selective catalytic reduction with high nitrogen conversion rates is obtained.

Self-locking inverter

Die Erfindung betrifft einen Umrichter (1) mit einem Zwischenkreis (3) zum Bereitstellen einer Gleichspannung (10) zwischen einer Plusleitung (11) und einer Minusleitung (12), einer Phasenleitung (8, 9) zum Empfangen und/oder Ausgeben einer Wechselspannung und einer Halbbrückenschaltung (17) mit einer ersten Schalteranordnung (18) zum Verbinden der Plusleitung (11) mit der Phasenleitung (8, 9) und einer zweiten Schalteranordnung (19) zum Verbinden der Minusleitung (12) mit der Phasenleitung (8, 9). Bei einem Defekt eines Halbleiterschalters (20, 21) des Umrichters (1) soll sich der Umrichter (1) selbst sichern und weiterbetrieben werden können. Hierzu weist die erste Schalteranordnung (18) und die zweite Schalteranordnung (19) jeweils eine Parallelschaltung aus mehreren Schaltzweigen (Z) auf und in jedem Schaltzweig (Z) ist einer der Halbleiterschalter (20, 21) mit einer eigenen, in Reihe zur Schaltstrecke des Halbleiterschalters (20, 21) geschalteten Schmelzsicherung (22) bereitgestellt. The invention relates to an inverter (1) with an intermediate circuit (3) for providing a DC voltage (10) between a positive line (11) and a negative line (12), a phase line (8, 9) for receiving and / or outputting an AC voltage and a half-bridge circuit (17) having a first switch arrangement (18) for connecting the positive line (11) to the phase line (8, 9) and a second switch arrangement (19) for connecting the negative line (12) to the phase line (8, 9). In the event of a defect of a semiconductor switch (20, 21) of the converter (1), the converter (1) should be able to secure itself and continue to operate. For this purpose, the first switch arrangement (18) and the second switch arrangement (19) each have a parallel circuit of a plurality of switching branches (Z) and in each switching branch (Z) is one of the semiconductor switches (20, 21) with its own, in series with the switching path of Semiconductor switch (20, 21) switched fuse (22) provided.

method of producing a therapeutic vaccine composition, antigenic construct, vaccine composition, uses of an antigenic construct, and, method of preparing and producing a medicament for the treatment of a condition or disease associated with amyloid

método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um fragmento de peptídeo antigênico abeta, de um antígeno de peptídeo abeta ou um construto antigênico, métodos para tratar uma condição ou doença associada com amilóide, para significativamente aumentar a retenção ou capacidade de memória cognitiva de um mamífero, para induzir uma resposta imune em um animal, para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide, e, anticorpo ou mistura de anticorpos. a presente invenção refere-se aos métodos e às composições para o uso diagnóstico e terapêutico no tratamento de doenças e de distúrbios que são causados por ou estão associados com proteínas amilóide ou tipo-amilóide incluindo amiloidose. em particular, a presente invenção proporciona novos métodos e composições para gerar uma resposta imune elevadamente específica e elevadamente efetiva em um organismo, mas particularmente dentro de um animal, particularmente um mamífero ou um humano, que é capaz de prevenir ou de aliviar amiloidose, ou os sintomas associados com amiloidose, um grupo de doenças e distúrbios associados com formação de placa amilóide incluindo amiloidose secundária e amiloidose relacionada com a idade incluindo, mas não limitado a, distúrbios neurológicos tal como mal de alzheimer (ad), incluindo doenças ou condições caracterizadas por uma perda de capacidade de memória cognitiva tal como, por exemplo, debilitação cognitiva suave (mci). method for producing a therapeutic vaccine composition, antigenic construct, vaccine composition, uses of an abeta antigenic peptide fragment, an abeta peptide antigen or an antigenic construct, methods to treat a condition or disease associated with amyloid, to significantly increase the retention or cognitive memory capacity of a mammal to induce an immune response in an animal to prepare and produce a medicament for the treatment of a condition or disease ...

Portable sprayer

Die Erfindung betrifft ein tragbares Sprühgerät (1). Das Sprühgerät (1) ist zum wahlweisen Ausbringen von flüssigen Sprühmitteln und feststofförmigen Stäubemitteln mit einem von einem Gebläse (6) erzeugten Gebläseluftstrom (7) vorgesehen. Es ist ein lösbar mit einem Vorratsbehälter (4) verbundener Adapter (8) vorgesehen, der mindestens einen Kanalabschnitt (9) eines Flüssigkeitskanals (10) für das flüssige Sprühmittel sowie einen Kanalabschnitt (11) eines Feststoffkanals (12) für das feststofförmige Stäubemittel aufweist. Der Flüssigkeitskanal (10) und der Feststoffkanal (12) münden in den Gebläseluftstrom (7). Verschiedene Einbaulagen des Vorratsbehälters (4) und des Adapters (8) relativ zueinander und zur Gebläseeinheit (3) sind seitens des Benutzers frei wählbar. In einer Einbaulage steht der Flüssigkeitskanal (10) über dessen Kanalabschnitt (9) und in einer anderen Einbaulage der Feststoffkanal (12) über dessen Kanalabschnitt (11) mit einem Innenraum (13) des Vorratsbehälters (4) in Verbindung. The invention relates to a portable spray device (1). The spray device (1) is provided for selectively discharging liquid sprays and solid dusts with a blower air flow (7) generated by a blower (6). An adapter (8) detachably connected to a reservoir (4) is provided which has at least one channel section (9) of a liquid channel (10) for the liquid spray and a channel section (11) of a solid channel (12) for the solid dust. The liquid channel (10) and the solids channel (12) open into the forced air flow (7). Various mounting positions of the reservoir (4) and the adapter (8) relative to each other and to the blower unit (3) are freely selectable by the user. In an installed position, the liquid channel (10) via the channel portion (9) and in another mounting position of the solid channel (12) via the channel portion (11) with an interior (13) of the reservoir (4) in connection.

WASTE COLLECTOR

PHARMACEUTICAL COMPOSITION

La presente invención se refiere a métodos y composiciones farmaceuticas para el uso terapeutico y diagnostico del tratamiento de enfermedades y trastornos que son causados por o asociados con ovillos neurofibrilares.

Harness

A harness has a support base and a support strap unit for the support base, and a holding device for releasably holding a battery pack in a support position on the support base. The holding device has a docking mechanism on the support base for pivotably docking the battery pack in a docking position, and a securing mechanism for securing the battery pack in the support position pivoted in towards the support base with respect to the docking position. The docking mechanism is arranged on a lower region of the support base, and the securing mechanism has a securing slide which is arranged displaceably on the support base between a release position and a securing position and has a securing hook, or a securing lever which is arranged pivotably on the support base between a release position and a securing position and has a securing bow. The securing hook or securing bow is designed to engage securely behind a corresponding mating securing element of the battery pack in the support position.